WEST BRIDGEWATER, Mass.--(BUSINESS WIRE)--Oct. 10, 2006--Pressure BioSciences, Inc. (NASDAQ: PBIO) today announced that it has sold Bench Top (NEP3229) PCT Sample Preparation Systems (PCT SPS) to Johns Hopkins University, the National Institutes of Health (NIH), and a state laboratory of the Commonwealth of Virginia. The PCT Sample Preparation Systems were installed at all three sites prior to the close of the Company's quarter ended September 30, 2006.
Richard T. Schumacher, Founder, President, and CEO of Pressure BioSciences, commented: "We are of course pleased that Johns Hopkins, the NIH, and a state laboratory in Virginia have purchased PCT Sample Preparation Systems. The sale of our PCT Sample Preparation Systems to such prestigious institutions, the recent award of a NIH SBIR Phase I grant (10/4/06 press release), and the on-going generation of new and exciting data by both our laboratory and the laboratories of our collaborators and customers are key milestones reached in our goal to gain acceptance for the PCT SPS for a variety of applications in academic, government, and industrial laboratories."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.
Forward Looking Statements
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, unforeseen technological difficulties that the Company may encounter in the development of the PCT technology and the PCT SPS, the possibility that the Company's and its collaborator's experiments may not demonstrate the continued effective use of PCT in the extraction of proteins and nucleic acids from cells and tissues, the possibility that the Company's PCT technology and PCT SPS may not be accepted by the commercial market as a needed improvement over current extraction methods, and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-QSB for the quarter ended June 30, 2006, in the Company's Annual Report on Form 10-KSB, as amended, for the year ended December 31, 2005, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
Visit us at our website http://www.pressurebiosciences.com.
CONTACT: Pressure BioSciences, Inc.
Richard T. Schumacher, 508-580-1818
President & CEO
or
Edward H. Myles, 508-580-1818
Vice President of Finance & CFO
SOURCE: Pressure BioSciences, Inc.